Bright Minds Biosciences
Open
$87.75
Prev. Close
$87.75
High
$87.92
Low
$87.50
Market Snapshot
$680.43M
-46.9
-0.18
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
emptyResult
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Recently from Cashu
Bright Minds Biosciences Inc. Must Adapt to Novo Nordisk's Price Changes in Obesity Market
Novo Nordisk's Strategic Price Adjustments in the Obesity Drug Market Novo Nordisk's recent announcement to offer its weight-loss drug, Wegovy, at a reduced price of $499 per month for cash-paying pat…
Supreme Court Case May Redefine Liability Standards for Bright Minds Biosciences Inc.
Legal Liability in Focus: The Impending Supreme Court Case and Its Implications for Bright Minds Biosciences Inc A pivotal case currently pending before the Supreme Court of the United States holds si…
Supreme Court Case May Impact Liability Standards for Bright Minds Biosciences Inc.
Implications of a Landmark Supreme Court Case on Liability Standards A pivotal case currently before the Supreme Court is poised to redefine liability standards in the United States, with far-reaching…
Bright Minds Biosciences Inc. Fosters Innovation in Cannabis Withdrawal with FDA Fast Track Designation
PleoPharma Advances Treatment for Cannabis Withdrawal Syndrome with FDA Fast Track Designation PleoPharma, Inc., a clinical-stage biopharmaceutical company based in Phoenixville, Pennsylvania, recentl…